InnoCare says Zenas-partnered drug succeeds in China study in form of lupus

InnoCare Pharma’s experimental oral BTK inhibitor, called orelabrutinib, succeeded in a mid-stage trial in systemic lupus erythematosus (SLE), the Chinese biotech said Sunday. After nearly a year’s worth of treatment with ...